Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine

What’s new in metastatic pancreatic cancer management?

Date

22 Nov 2019

Session

AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine

Topics

Cytotoxic Therapy

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Talia Golan

Authors

T. Golan

Author affiliations

  • Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction

Presenter: Byoung-Gie Kim

Session: AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine

Resources:

Slides

Webcast

Closing

Presenter: Byoung-Gie Kim

Session: AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine

Resources:

Slides

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.